Please Note: This trial is no longer enrolling new participants
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA
| Protocol No. | CTO-GO44479 | Scope | National |
|---|---|---|---|
| Principal Investigator | Anita Turk | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
